NASDAQ:ELEV Elevation Oncology (ELEV) Stock Price, News & Analysis → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free ELEV Stock Alerts $3.70 -0.12 (-3.14%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$3.69▼$4.1350-Day Range$2.90▼$5.1752-Week Range$0.36▼$5.89Volume431,646 shsAverage Volume880,879 shsMarket Capitalization$202.17 millionP/E RatioN/ADividend YieldN/APrice Target$7.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Elevation Oncology alerts: Email Address Elevation Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside95.9% Upside$7.25 Price TargetShort InterestBearish13.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.04Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.87) to ($0.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.29 out of 5 starsMedical Sector2977th out of 5,424 stocksBiological Products, Except Diagnostic Industry466th out of 909 stocks 3.5 Analyst's Opinion Consensus RatingElevation Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageElevation Oncology has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.03% of the float of Elevation Oncology has been sold short.Short Interest Ratio / Days to CoverElevation Oncology has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Elevation Oncology has recently decreased by 1.20%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldElevation Oncology does not currently pay a dividend.Dividend GrowthElevation Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELEV. Previous Next 2.2 News and Social Media Coverage News SentimentElevation Oncology has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Elevation Oncology this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for ELEV on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat Follows4 people have added Elevation Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Elevation Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders14.90% of the stock of Elevation Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.70% of the stock of Elevation Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Elevation Oncology are expected to grow in the coming year, from ($0.87) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elevation Oncology is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elevation Oncology is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElevation Oncology has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad AltimetryStock-Picking AI Predicts #1 Stock of 2024Since the start of the year, the top 10 investment funds in the world – including Vanguard, Blackrock, Fidelity and JP Morgan – have made nearly $1 trillion in profits on these 7 stocks.Click here to learn what's coming (and how to prepare). About Elevation Oncology Stock (NASDAQ:ELEV)Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Read More ELEV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELEV Stock News HeadlinesMay 5, 2024 | americanbankingnews.comElevation Oncology (NASDAQ:ELEV) Stock Rating Reaffirmed by WedbushMay 4, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Elevation Oncology (ELEV), Moderna (MRNA)May 5, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.May 2, 2024 | markets.businessinsider.comHint Health Announces 8th Annual Hint Summit, the Leading DPC Innovation ConferenceMay 2, 2024 | msn.comElevation Oncology GAAP EPS of -$0.23May 2, 2024 | marketwatch.comElevation Oncology Shares Swing to 5% Gain After Extending Cash RunwayMay 2, 2024 | msn.comELEV Stock Earnings: Elevation Oncology Misses EPS for Q1 2024May 2, 2024 | prnewswire.comElevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsMay 5, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.April 26, 2024 | finance.yahoo.comClariane: First Quarter 2024 RevenueApril 22, 2024 | seekingalpha.comElevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)April 10, 2024 | msn.comBiologic drug-device combination immunotherapy for metastatic prostate cancer patientsApril 9, 2024 | markets.businessinsider.comPromising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation OncologyApril 8, 2024 | finance.yahoo.comElevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024March 28, 2024 | msn.comDesign for proposed southern Utah reservoir is poor and poses risk to public safety, geophysicist saysMarch 28, 2024 | msn.comMelanoma: All about the risks, symptoms, and common mythsMarch 27, 2024 | msn.comUp 825% So Far in 2024, Can This Penny Stock Go Any Higher?March 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)March 9, 2024 | benzinga.comElevation Oncology Stock (NASDAQ:ELEV), Quotes and News SummaryMarch 8, 2024 | investorplace.comAll Three of Our Analysts AgreeMarch 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Elevation Oncology (ELEV) and OrthoPediatrics (KIDS)March 7, 2024 | finance.yahoo.comElevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023March 6, 2024 | markets.businessinsider.comElevation Oncology, Inc. Q4 Loss decreases, beats estimatesMarch 6, 2024 | msn.comELEV Stock Earnings: Elevation Oncology Beats EPS for Q4 2023March 6, 2024 | finance.yahoo.comElevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024March 6, 2024 | finance.yahoo.comElevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business AchievementsMarch 5, 2024 | investorplace.comTrim the Fat: 3 Overbought Stocks Poised for a PullbackSee More Headlines Receive ELEV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today5/05/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ELEV CUSIPN/A CIK1783032 Webwww.elevationoncology.com Phone716-371-1125FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price Target$7.25 High Stock Price Target$8.00 Low Stock Price Target$6.00 Potential Upside/Downside+95.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.33% Return on Assets-39.43% Debt Debt-to-Equity Ratio0.55 Current Ratio21.22 Quick Ratio21.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book2.87Miscellaneous Outstanding Shares54,640,000Free Float46,497,000Market Cap$202.17 million OptionableOptionable Beta1.52 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. David Dornan Ph.D. (Age 46)Chief Scientific Officer Comp: $545.5kMs. Valerie Malyvanh Jansen M.D. (Age 46)Ph.D., Chief Medical Officer Comp: $641.53kMr. Joseph J. Ferra Jr. (Age 49)CEO, President & Director Comp: $391.52kMs. Tammy Furlong CPAP.M.P., CFO & SecretaryMr. Ryan BloomerHead of Tech OpsCandice MasseSenior Director of Corporate Communications & Investor RelationsMr. Robert C. YangVice President of Legal AffairsMore ExecutivesKey CompetitorsGenfitNASDAQ:GNFTKodiak SciencesNASDAQ:KODCompugenNASDAQ:CGEN10X Capital Venture Acquisition Corp. IIINYSE:VCXBZura BioNASDAQ:ZURAView All Competitors ELEV Stock Analysis - Frequently Asked Questions Should I buy or sell Elevation Oncology stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elevation Oncology in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELEV shares. View ELEV analyst ratings or view top-rated stocks. What is Elevation Oncology's stock price target for 2024? 5 Wall Street research analysts have issued twelve-month target prices for Elevation Oncology's stock. Their ELEV share price targets range from $6.00 to $8.00. On average, they expect the company's stock price to reach $7.25 in the next twelve months. This suggests a possible upside of 95.9% from the stock's current price. View analysts price targets for ELEV or view top-rated stocks among Wall Street analysts. How have ELEV shares performed in 2024? Elevation Oncology's stock was trading at $0.5370 at the start of the year. Since then, ELEV stock has increased by 589.0% and is now trading at $3.70. View the best growth stocks for 2024 here. Are investors shorting Elevation Oncology? Elevation Oncology saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,010,000 shares, an increase of 8.2% from the March 15th total of 4,630,000 shares. Based on an average daily trading volume, of 3,060,000 shares, the short-interest ratio is presently 1.6 days. Currently, 12.6% of the company's shares are sold short. View Elevation Oncology's Short Interest. When is Elevation Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our ELEV earnings forecast. How were Elevation Oncology's earnings last quarter? Elevation Oncology, Inc. (NASDAQ:ELEV) posted its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.02. When did Elevation Oncology IPO? Elevation Oncology (ELEV) raised $1 billion in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share. How do I buy shares of Elevation Oncology? Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELEV) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
